Lumentum stock sinks after revenue misses amid deployment delays, downbeat outlook

Referenced Symbols

Shares of Lumentum Holdings Inc. LITE, +1.70% sank 6.5% toward a seven-month low in premarket trading Wednesday, after the optical and photonic products company reported a fiscal third-quarter profit that matched expectations but revenue that missed, citing deployment delays in China, and provided a downbeat outlook. Net income jumped to $225.5 million, or $2.85 a share, from $43.4 million, or 56 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $1.40 from $1.26, matching the FactSet consensus of $1.40. Revenue increased 4.1% to $419.5 million, below the FactSet consensus of $433.4 million. "Out of an abundance of caution, we deferred $14.8 million of revenue due to delays in 5G deployments in China, which decreased our reported revenue accordingly," said Chief Executive Alan Lowe. For the fourth quarter, the company expects adjusted EPS of 92 cents to $1.14 and revenue of $360 million to $400 million, both below the FactSet consensus for EPS of $1.25 and for revenue of $410 million. Lumentum's stock has dropped 12.6% over the past three months through Tuesday, while the S&P 500 SPX, -0.87% has gained 5.5%.

Read Next

Read Next

India’s COVID crisis deepens, as BioNTech says there’s no evidence its vaccine needs adapting to cope with new variants

The global tally of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 158 million on Monday, as cases continue to surge in Southeast Asia, and especially India, and BioNTech said there's no evidence the vaccine it developed with Pfizer Inc. needs adapting to protect against variants.

More On MarketWatch

About the Author